Mutant Native Outer Membrane Vesicles Combined with a Serogroup A Polysaccharide Conjugate Vaccine for Prevention of Meningococcal Epidemics in Africa

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Pajon, Rolando ^a   Fergus, Andrew M ^a   Granoff, Dan M ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; ENDOTOXIN; IMMUNOGLOBULIN G; MENINGOCOCCAL QUADRIVALENT CONJUGATE VACCINE; MENINGOCOCCAL SEROGROUP A POLYSACCHARIDE CONJUGATE VACCINE; UNCLASSIFIED DRUG; VACCINE; BACTERIAL POLYSACCHARIDE; MENINGOCOCCAL GROUP A POLYSACCHARIDE; MENINGOCOCCUS VACCINE;

AFRICA; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; EPIDEMIC; GAMBIA; GENE EXPRESSION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; MEMBRANE VESICLE; MENINGOCOCCEMIA; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; OUTER MEMBRANE; POLYACRYLAMIDE GEL ELECTROPHORESIS; AFRICA SOUTH OF THE SAHARA; ANIMAL; FEMALE; GENETICS; IMMUNOLOGY; MENINGITIS, MENINGOCOCCAL;

MUS;

AFRICA SOUTH OF THE SAHARA; ANIMALS; FEMALE; HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; MICE; NEISSERIA MENINGITIDIS, SEROGROUP A; POLYSACCHARIDES, BACTERIAL; VACCINES, CONJUGATE;

EID: 84879259511     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066536     Document Type: Article

References (94)

1. Greenwood B, (1999) Manson Lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 93: 341-353.
2. Harrison LH, (2010) Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis 50Suppl 2: S37-44.
3. Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, et al. (2010) Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 50: 184-191.
4. Harrison LH, Trotter CL, Ramsay ME, (2009) Global epidemiology of meningococcal disease. Vaccine 27Suppl 2: B51-63.
5. Jodar L, LaForce FM, Ceccarini C, Aguado T, Granoff DM, (2003) Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet 361: 1902-1904.
6. Lee CH, Kuo WC, Beri S, Kapre S, Joshi JS, et al. (2009) Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa. Vaccine 27: 726-732.
7. Bishai DM, Champion C, Steele ME, Thompson L, (2011) Product development partnerships hit their stride: lessons from developing a meningitis vaccine for Africa. Health affairs 30: 1058-1064.
8. Marc LaForce F, Ravenscroft N, Djingarey M, Viviani S, (2009) Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine 27Suppl 2: B13-19.
9. Sow SO, Okoko BJ, Diallo A, Viviani S, Borrow R, et al. (2011) Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 364: 2293-2304.
10. Djingarey MH, Barry R, Bonkoungou M, Tiendrebeogo S, Sebgo R, et al. (2012) Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. Vaccine 30Suppl 2: B40-45.
11. Novak RT, Kambou JL, Diomande FV, Tarbangdo TF, Ouedraogo-Traore R, et al. (2012) Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis 12: 757-764.
12. Kristiansen PA, Diomande F, Ba AK, Sanou I, Ouedraogo AS, et al. (2012) Impact of the Serogroup A Meningococcal Conjugate Vaccine, MenAfriVac, on Carriage and Herd Immunity. Clin Infect Dis DOI 10.1093/cid/cis892.
13. Mueller JE, Borrow R, Gessner BD, (2006) Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines. Expert Rev Vaccines 5: 319-336.
14. Boisier P, Nicolas P, Djibo S, Taha MK, Jeanne I, et al. (2007) Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 44: 657-663.
15. Halperin SA, Bettinger JA, Greenwood B, Harrison LH, Jelfs J, et al. (2012) The changing and dynamic epidemiology of meningococcal disease. Vaccine 30Suppl 2: B26-36.
16. Pace D, (2009) MenACWY-CRM, a novel quadrivalent glycoconjugate vaccine against Neisseria meningitidis for the prevention of meningococcal infection. Curr Opin Mol Ther 11: 692-706.
17. Gasparini R, Panatto D, (2011) Meningococcal glycoconjugate vaccines. Hum Vaccin 7: 170-182.
18. Harrison LH, Mohan N, Kirkpatrick P, (2010) Meningococcal group A, C, Y and W-135 conjugate vaccine. Nat Rev Drug Discov 9: 429-430.
19. Harrison LH, (2008) A multivalent conjugate vaccine for prevention of meningococcal disease in infants. JAMA 299: 217-219.
20. Finne J, Leinonen M, Makela PH, (1983) Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 2: 355-357.
21. Masignani V, Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, et al. (2003) Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 197: 789-799.
22. Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, et al. (2004) Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 72: 2088-2100.
23. Madico G, Welsch JA, Lewis LA, McNaughton A, Perlman DH, et al. (2006) The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 177: 501-510.
24. Welsch JA, Ram S, (2008) Factor H and Neisserial pathogenesis. Vaccine 26Suppl 8: I40-45.
25. Mothibeli KM, du Plessis M, von Gottberg A, Murphy E, Hoiseth SK, et al. (2011) Distribution of factor H binding protein beyond serogroup B: variation among five serogroups of invasive Neisseria meningitidis in South Africa. Vaccine 29: 2187-2192.
26. Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, et al. (2009) Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 200: 379-389.
27. Findlow J, Borrow R, Snape MD, Dawson T, Holland A, et al. (2010) Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 51: 1127-1137.
28. Snape MD, Dawson T, Oster P, Evans A, John TM, et al. (2010) Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 29: e71-79.
29. Richmond PC, Nissen MD, Marshall HS, Lambert SB, Roberton D, et al. (2012) A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: Results of a randomised, controlled, dose-escalation phase 1 trial. Vaccine 30: 6163-6174.
30. Marshall HS, Richmond PC, Nissen MD, Jiang Q, Anderson AS, et al. (2012) Safety and Immunogenicity of a Meningococcal B Bivalent rLP2086 Vaccine in Healthy Toddlers Aged 18-36 Months: A Phase 1 Randomized-controlled Clinical Trial. Pediatr Infect Dis J 31: 1061-1068.
31. Richmond PC, Marshall HS, Nissen MD, Jiang Q, Jansen KU, et al. (2012) Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 12: 597-607.
32. Granoff DM (2012) European Medicines Agency Recommends Approval of a Broadly Protective Vaccine against Serogroup B Meningococcal Disease. Pediatr Infect Dis J DOI: 10.1097/INF.0b013e318282942f.
33. Scarselli M, Arico B, Brunelli B, Savino S, Di Marcello F, et al. (2011) Rational design of a meningococcal antigen inducing broad protective immunity. Sci Transl Med 3: 91ra62.
34. Beernink PT, Granoff DM, (2008) Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines. Infect Immun 76: 2568-2575.
35. Giuliani MM, Adu-Bobie J, Comanducci M, Arico B, Savino S, et al. (2006) A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 103: 10834-10839.
36. Koeberling O, Seubert A, Granoff DM, (2008) Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin. J Infect Dis 198: 262-270.
37. Koeberling O, Seubert A, Santos G, Colaprico A, Ugozzoli M, et al. (2011) Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys. Vaccine 29: 4728-4734.
38. Pajon R, Beernink PT, Harrison LH, Granoff DM, (2010) Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine 28: 2122-2129.
39. Seib KL, Brunelli B, Brogioni B, Palumbo E, Bambini S, et al. (2011) Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies. Infect Immun 79: 970-981.
40. Brunelli B, Del Tordello E, Palumbo E, Biolchi A, Bambini S, et al. (2011) Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1. Vaccine 29: 1072-1081.
41. Jiang HQ, Hoiseth SK, Harris SL, McNeil LK, Zhu D, et al. (2010) Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 28: 6086-6093.
42. Pajon R, Fergus AM, Koeberling O, Caugant DA, Granoff DM, (2011) Meningococcal factor h binding proteins in epidemic strains from Africa: implications for vaccine development. PLoS Negl Trop Dis 5: e1302.
43. Beernink PT, Shaughnessy J, Pajon R, Braga EM, Ram S, et al. (2012) The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein. PLoS Pathog 8: e1002688.
44. Beernink PT, Shaughnessy J, Braga EM, Liu Q, Rice PA, et al. (2011) A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol 186: 3606-3614.
45. Pajon R, Beernink PT, Granoff DM, (2012) Design of meningococcal factor H binding protein mutant vaccines that do not bind human complement factor H. Infect Immun. 80: 2667-2677.
46. Caugant DA, Kristiansen PA, Wang X, Mayer LW, Taha MK, et al. (2012) Molecular Characterization of Invasive Meningococcal Isolates from Countries in the African Meningitis Belt before Introduction of a Serogroup A Conjugate Vaccine. PLoS One 7: e46019.
47. Beernink PT, LoPasso C, Angiolillo A, Felici F, Granoff D, (2009) A region of the N-terminal domain of meningococcal factor H-binding protein that elicits bactericidal antibody across antigenic variant groups. Mol Immunol 46: 1647-1653.
48. Giuntini S, Reason DC, Granoff DM, (2011) Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding. Infect Immun 79: 3751-3759.
49. Steeghs L, Tommassen J, Leusen JH, van de Winkel JG, van der Ley P, (2004) Teasing apart structural determinants of 'toxicity' and 'adjuvanticity': implications for meningococcal vaccine development. J Endotoxin Res 10: 113-119.
50. Koeberling O, Giuntini S, Seubert A, Granoff DM, (2009) Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2. Clin Vaccine Immunol 16: 156-162.
51. Zollinger WD, Donets MA, Schmiel DH, Pinto VB, Labrie J, et al. (2010) Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine. Vaccine 28: 5057-5067.
52. Findlow H, Sow S, Borrow R, Tapia M, Haidara FC, et al. (2011) Meningococcal group C and W135 immunological hyporesponsiveness in african toddlers. Clin Vaccine Immunol 18: 1492-1496.
53. Keyserling H, Papa T, Koranyi K, Ryall R, Bassily E, et al. (2005) Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 159: 907-913.
54. Welsch JA, Rossi R, Comanducci M, Granoff DM, (2004) Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J Immunol 172: 5606-5615.
55. Granoff DM, Maslanka SE, Carlone GM, Plikaytis BD, Santos GF, et al. (1998) A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses. Clin Diagn Lab Immunol 5: 479-485.
56. Kogan G, Uhrin D, Brisson JR, Jennings HJ, (1997) Structural basis of the Neisseria meningitidis immunotypes including the L4 and L7 immunotypes. Carbohydr Res 298: 191-199.
57. Tsang RS, Law DK, Tsai C, Ng L, (2001) Detection of the lst gene in different serogroups and LOS immunotypes of Neisseria meningitidis. FEMS Microbiol Lett 199: 203-206.
58. Smith H, Parsons NJ, Cole JA, (1995) Sialylation of neisserial lipopolysaccharide: a major influence on pathogenicity. Microb Pathog 19: 365-377.
59. Beernink PT, Caugant DA, Welsch JA, Koeberling O, Granoff DM, (2009) Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa. J Infect Dis 199: 1360-1368.
60. Wang JF, Caugant DA, Li X, Hu X, Poolman JT, et al. (1992) Clonal and antigenic analysis of serogroup A Neisseria meningitidis with particular reference to epidemiological features of epidemic meningitis in the People's Republic of China. Infect Immun 60: 5267-5282.
61. Dempsey JA, Wallace AB, Cannon JG, (1995) The physical map of the chromosome of a serogroup A strain of Neisseria meningitidis shows complex rearrangements relative to the chromosomes of the two mapped strains of the closely related species N. gonorrhoeae. J Bacteriol 177: 6390-6400.
62. Koeberling O, Delany I, Granoff DM, (2011) A critical threshold of meningococcal factor h binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines. Clin Vaccine Immunol 18: 736-742.
63. Lewis LA, Ngampasutadol J, Wallace R, Reid JE, Vogel U, et al. (2010) The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog 6: e1001027.
64. Xie O, Bolgiano B, Gao F, Lockyer K, Swann C, et al. (2012) Characterization of size, structure and purity of serogroup X Neisseria meningitidis polysaccharide, and development of an assay for quantification of human antibodies. Vaccine 30: 5812-5823.
65. LaForce FM, Konde K, Viviani S, Preziosi MP, (2007) The Meningitis Vaccine Project. Vaccine 25Suppl 1: A97-100.
66. Broker M, Dull PM, Rappuoli R, Costantino P, (2009) Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages. Vaccine 27: 5574-5580.
67. Jackson LA, Jacobson RM, Reisinger KS, Anemona A, Danzig LE, et al. (2009) A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J: 86-91.
68. Perrett KP, Snape MD, Ford KJ, John TM, Yu LM, et al. (2009) Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr Infect Dis J 28: 186-193.
69. Dagan R, Poolman J, Siegrist CA, (2010) Glycoconjugate vaccines and immune interference: A review. Vaccine 28: 5513-5523.
70. Nokleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, et al. (2007) Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Vaccine 25: 3080-3084.
71. Sierra GV, Campa HC, Varcacel NM, Garcia IL, Izquierdo PL, et al. (1991) Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 14: 195-207; discussion 208-110.
72. Galloway Y, Stehr-Green P, McNicholas A, O'Hallahan J, (2009) Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol 38: 413-418.
73. Norheim G, Tunheim G, Naess LM, Kristiansen PA, Caugant DA, et al. (2012) An outer membrane vesicle vaccine for prevention of serogroup A and W-135 meningococcal disease in the African meningitis belt. Scand J Immunol 76: 99-107.
74. Tappero JW, Lagos R, Ballesteros AM, Plikaytis B, Williams D, et al. (1999) Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 281: 1520-1527.
75. Suker J, Feavers IM, Achtman M, Morelli G, Wang JF, et al. (1994) The porA gene in serogroup A meningococci: evolutionary stability and mechanism of genetic variation. Mol Microbiol 12: 253-265.
76. Feavers IM, Heath AB, Bygraves JA, Maiden MC, (1992) Role of horizontal genetic exchange in the antigenic variation of the class 1 outer membrane protein of Neisseria meningitidis. Mol Microbiol 6: 489-495.
77. Caugant DA, Nicolas P, (2007) Molecular surveillance of meningococcal meningitis in Africa. Vaccine 25Suppl 1: A8-11.
78. Norheim G, Rosenqvist E, Aseffa A, Yassin MA, Mengistu G, et al. (2006) Characterization of Neisseria meningitidis isolates from recent outbreaks in Ethiopia and comparison with those recovered during the epidemic of 1988 to 1989. J Clin Microbiol 44: 861-871.
79. Nicolas P, Norheim G, Garnotel E, Djibo S, Caugant DA, (2005) Molecular epidemiology of Neisseria meningitidis isolated in the African Meningitis Belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes. J Clin Microbiol 43: 5129-5135.
80. Jelfs J, Munro R, Wedege E, Caugant DA, (2000) Sequence variation in the porA gene of a clone of Neisseria meningitidis during epidemic spread. Clin Diagn Lab Immunol 7: 390-395.
81. Keiser PB, Biggs-Cicatelli S, Moran EE, Schmiel DH, Pinto VB, et al. (2011) A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 29: 1423-1420.
82. Ferrari G, Garaguso I, Adu-Bobie J, Doro F, Taddei AR, et al. (2006) Outer membrane vesicles from group B Neisseria meningitidis delta gna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles. Proteomics 6: 1856-1866.
83. Chiavolini D, Weir S, Murphy JR, Wetzler LM, (2008) Neisseria meningitidis PorB, a Toll-like receptor 2 ligand, improves the capacity of Francisella tularensis lipopolysaccharide to protect mice against experimental tularemia. Clin Vaccine Immunol 15: 1322-1329.
84. Wetzler LM, (2010) Innate immune function of the neisserial porins and the relationship to vaccine adjuvant activity. Future Microbiol 5: 749-758.
85. Zughaier S, Steeghs L, van der Ley P, Stephens DS, (2007) TLR4-dependent adjuvant activity of Neisseria meningitidis lipid A. Vaccine. 25: 4401-4409.
86. Vu DM, Wong TT, Granoff DM, (2011) Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and Neisserial heparin binding antigen. Vaccine 29: 1968-1973.
87. Greenwood B, (2007) The changing face of meningococcal disease in West Africa. Epidemiol Infect 135: 703-705.
88. Stephens DS, Greenwood B, Brandtzaeg P, (2007) Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 369: 2196-2210.
89. Ibarz-Pavon AB, Morais L, Sigauque B, Mandomando I, Bassat Q, et al. (2011) Epidemiology, molecular characterization and antibiotic resistance of Neisseria meningitidis from patients
90. Gray-Owen SD, (2003) Neisserial Opa proteins: impact on colonization, dissemination and immunity. Scand J Infect Dis 35: 614-618.
91. Popp A, Dehio C, Grunert F, Meyer TF, Gray-Owen SD, (1999) Molecular analysis of neisserial Opa protein interactions with the CEA family of receptors: identification of determinants contributing to the differential specificities of binding. Cell Microbiol 1: 169-181.
92. Poolman JT, Kriz-Kuzemenska P, Ashton F, Bibb W, Dankert J, et al. (1995) Serotypes and subtypes of Neisseria meningitidis: results of an international study comparing sensitivities and specificities of monoclonal antibodies. Clin Diagn Lab Immunol 2: 69-72.
93. Maiden MC, Bygraves JA, Feil E, Morelli G, Russell JE, et al. (1998) Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A 95: 3140-3145.
94. Jolley KA, Maiden MC, (2010) BIGSdb: Scalable analysis of bacterial genome variation at the population level. BMC Bioinformatics 11: 595.